{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T17:05:46Z","timestamp":1786122346603,"version":"build-2736575974"},"reference-count":49,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"funder":[{"DOI":"10.13039\/100019944","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019944","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Economics"],"published-print":{"date-parts":[[2026,12,31]]},"DOI":"10.1080\/13696998.2026.2709297","type":"journal-article","created":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T10:03:26Z","timestamp":1786097006000},"page":"2107-2120","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Clinical and economic outcomes of cabazitaxel versus Lu-PSMA in mCRPC: a US perspective"],"prefix":"10.1080","volume":"29","author":[{"given":"Braydon","family":"Nault","sequence":"first","affiliation":[{"name":"EVERSANA Inc","place":["Burlington, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Garcia","sequence":"additional","affiliation":[{"name":"EVERSANA Inc","place":["Burlington, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Cameron","sequence":"additional","affiliation":[{"name":"EVERSANA Inc","place":["Burlington, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Revel","sequence":"additional","affiliation":[{"name":"Sanofi","place":["Morristown, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Steele","sequence":"additional","affiliation":[{"name":"Sanofi","place":["Morristown, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle","family":"Flannery","sequence":"additional","affiliation":[{"name":"Sanofi","place":["Morristown, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Barata","sequence":"additional","affiliation":[{"name":"University Hospitals Seidman Cancer Center","place":["Cleveland, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,8,7]]},"reference":[{"key":"e_1_3_4_2_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834"},{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.2147\/RRU.S385257"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911206"},{"key":"e_1_3_4_5_1","first-page":"17","article-title":"A systematic review of clinical practice guidelines for castration-resistant prostate cancer","volume":"17","author":"Foroughi Moghadam MJ","year":"2018","unstructured":"Foroughi Moghadam MJ, Taheri S, Peiravian F. A systematic review of clinical practice guidelines for castration-resistant prostate cancer. Iran J Pharm Res. 2018;17(Suppl):17\u201337.","journal-title":"Iran J Pharm Res"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/3941217"},{"key":"e_1_3_4_7_1","unstructured":"National Comprehensive Cancer Network. NCCN Guidelines Version 2.2026 prostate cancer. NCCN Clinical Practice Guidelines; 2025."},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-024-00906-z"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61389-X"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2015.07.037"},{"key":"e_1_3_4_11_1","volume-title":"Product monograph: PLUVICTO \u2013 lutetium (177Lu) vipivotide tetraxetan injection","author":"Novartis","year":"2025","unstructured":"Novartis. Product monograph: PLUVICTO \u2013 lutetium (177Lu) vipivotide tetraxetan injection. US Food and Drug Administration. 2025. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/215833s021s024lbl.pdf"},{"key":"e_1_3_4_12_1","doi-asserted-by":"crossref","unstructured":"Jo Y. Time from medication order to administration of cabazitaxel (C) vs. lutetium Lu-177 vipivotide tetraxetan (Lu) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). 2025. (#109) ASCO GU 2025. San Francisco California.","DOI":"10.1200\/JCO.2025.43.5_suppl.109"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00237-3"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00529-6"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-022-08274-x"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.2702"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"e_1_3_4_18_1","unstructured":"Healthcare Cost and Utilization Project. 2022. [Internet]. Available from: https:\/\/datatools.ahrq.gov\/hcupnet\/"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1177\/1078155213509505"},{"key":"e_1_3_4_20_1","unstructured":"October 2025 ASP Pricing. 2025. [Internet]. [cited 2025 Nov]. Available from: https:\/\/www.cms.gov\/medicare\/payment\/part-b-drugs\/asp-pricing-files"},{"key":"e_1_3_4_21_1","unstructured":"NAVLIN. 2025. [Internet]. Available from: https:\/\/data.navlin.com\/alspc\/#!\/homepage"},{"key":"e_1_3_4_22_1","unstructured":"Bureau of Labor Statistics. CPI\u2014All Urban Consumers (Current Series): medical care in U.S. city average all urban consumers not seasonally adjusted. May 22]. Available from: [Internet]. Washington (DC): U.S. Bureau of Labor Statistics; [cited. 2025. https:\/\/data.bls.gov\/cgi-bin\/surveymost?cu."},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-023-06255-8"},{"key":"e_1_3_4_24_1","unstructured":"Physician Fee Schedule 2025. 2025. [Internet]. Available from: https:\/\/www.cms.gov\/medicare\/physician-fee-schedule\/search\/overview"},{"key":"e_1_3_4_25_1","unstructured":"Jurisdiction 15 \u2013 CGS Q4 2024 Part B Drug Allowances. 2025. [Internet]. [cited 2025 Jun 25]. Available from: https:\/\/urldefense.com\/v3\/__https:\/\/www.cgsmedicare.com\/partb\/fees\/asp\/2024_asp_q4.html*:*:text=October*202021*20*2F*20Updated*20October 450*20Added*20January*202024__;I34lJSUlJSUlJQ!!IaTcZfFN!72dW1Qhrmrz0kw6k_UOmpWjQLh5wRRizcvePLyXMFIZIGTfsCVTacjVrxO2ptxzIDPeuyZFig65MoXnSucKoFg21Ksy_$"},{"key":"e_1_3_4_26_1","unstructured":"Jurisdiction 6 \u2013 NGS Radiopharmaceutical Pricing (J-6). 2025. [Internet]. [cited 2025 Jun 25]. Available from: https:\/\/urldefense.com\/v3\/__https:\/\/www.ngsmedicare.com\/web\/ngs\/search-details?selectedArticleId=4920515*:*:text=1*2F1*2F2025 1*2F13*2F2025*20*24259.45__;I34lJSUlJSU!!IaTcZfFN!72dW1Qhrmrz0kw6k_UOmpWjQLh5wRRizcvePLyXMFIZIGTfsCVTacjVrxO2ptxzIDPeuyZFig65MoXnSucKoFt4GSuVB$."},{"key":"e_1_3_4_27_1","unstructured":"Jurisdiction K \u2013 NGS Radiopharmaceutical Pricing (J-K). 2025. [Internet]. [cited June 25 2025]. Available from: https:\/\/urldefense.com\/v3\/__https:\/\/www.ngsmedicare.com\/web\/ngs\/search-details?selectedArticleId=4920515*:*:text=1*2F1*2F2025 1*2F13*2F2025*20*24259.45__;I34lJSUlJSU!!IaTcZfFN!72dW1Qhrmrz0kw6k_UOmpWjQLh5wRRizcvePLyXMFIZIGTfsCVTacjVrxO2ptxzIDPeuyZFig65MoXnSucKoFt4GSuVB$"},{"key":"e_1_3_4_28_1","unstructured":"Jurisdiction F \u2013 Radiopharmaceutical Fee Schedule. 2025. [Internet]. [cited 2025 Jun 25]. Available from: https:\/\/med.noridianmedicare.com\/web\/jfb\/fees-news\/fee-schedules\/radiopharmaceutical-fees"},{"key":"e_1_3_4_29_1","unstructured":"Jurisdiction E \u2013 Radiopharmaceutical Fee Schedule. 2025. [Internet]. [cited 2025 Jun 25]. Available from: https:\/\/med.noridianmedicare.com\/web\/jeb\/fees-news\/fee-schedules\/radiopharmaceutical-fees#:\u223c:text=A9606%20Xofigo%20Radium%20223%20%24174 00"},{"key":"e_1_3_4_30_1","unstructured":"Jurisdiction J \u2013 Palmetto GBA Q1 2025 Drug Fee Schedule. 2025. [Internet]. [cited 2025 Jun 25]. Available from: https:\/\/urldefense.com\/v3\/__https:\/\/dominoapps.palmettogba.com\/palmetto\/providers.nsf\/Files\/ASC_Drug_Fee_Schedule_Jan_2025.xlsx\/$FILE\/ASC_Drug_Fee_Schedule_Jan_2025.xlsx*:*:text=A9607*2C*20A*2C*20241 05*2C*20N*2C*200__;I34lJSUlJSUlJQ!!IaTcZfFN!72dW1Qhrmrz0kw6k_UOmpWjQLh5wRRizcvePLyXMFIZIGTfsCVTacjVrxO2ptxzIDPeuyZFig65MoXnSucKoFrZuKWdO$"},{"key":"e_1_3_4_31_1","unstructured":"Jurisdiction M \u2013 Palmetto GBA Q1 2025 Drug Fee Schedule. 2025. [Internet]. [cited 2025 Jun 25]. Available from: https:\/\/urldefense.com\/v3\/__https:\/\/dominoapps.palmettogba.com\/palmetto\/providers.nsf\/Files\/ASC_Drug_Fee_Schedule_Jan_2025.xlsx\/$FILE\/ASC_Drug_Fee_Schedule_Jan_2025.xlsx*:*:text=A9607*2C*20A*2C*20241 05*2C*20N*2C*200__;I34lJSUlJSUlJQ!!IaTcZfFN!72dW1Qhrmrz0kw6k_UOmpWjQLh5wRRizcvePLyXMFIZIGTfsCVTacjVrxO2ptxzIDPeuyZFig65MoXnSucKoFrZuKWdO$"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/94.24.1883"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0008933"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.33474"},{"key":"e_1_3_4_35_1","unstructured":"Physician Fee Schedule Search. 2020. [Internet]. [cited Nov 10]. Available from: https:\/\/www.cms.gov\/apps\/physician-fee-schedule\/"},{"key":"e_1_3_4_36_1","unstructured":"Clinical Laboratory Fee Schedule 2025. 2025. [Internet]. Available from: https:\/\/www.cms.gov\/medicare\/payment\/fee-schedules\/clinical-laboratory-fee-schedule-clfs\/files"},{"issue":"4","key":"e_1_3_4_37_1","first-page":"203","article-title":"Economic burden of toxicities associated with treating metastatic melanoma in the United States","volume":"9","author":"Bilir SP","year":"2016","unstructured":"Bilir SP, Ma Q, Zhao Z, et al. Economic burden of toxicities associated with treating metastatic melanoma in the United States. Am Health Drug Benefits. 2016;9(4):203\u2013213.","journal-title":"Am Health Drug Benefits"},{"issue":"7","key":"e_1_3_4_38_1","doi-asserted-by":"crossref","first-page":"e250032","DOI":"10.6004\/jnccn.2025.0032","article-title":"Adult cancer pain, Version 2.2025, NCCN clinical practice guidelines in oncology","volume":"23","author":"Swarm RA","year":"2025","unstructured":"Swarm RA, Youngwerth JM, Agne JL, et al. Adult cancer pain, Version 2.2025, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2025;23(7):e250032.","journal-title":"J Natl Compr Canc Netw"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-009-1056-z"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19960915)78:6<1314::AID-CNCR21>3.0.CO;2-2"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0049-3848(14)50021-7"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01399"},{"issue":"7","key":"e_1_3_4_43_1","first-page":"478","article-title":"Syncope evaluation and treatment guidelines from ACC, AHA, and HRS","volume":"97","author":"Hauk L.","year":"2018","unstructured":"Hauk L. Syncope evaluation and treatment guidelines from ACC, AHA, and HRS. Am Fam Physician. 2018;97(7):478\u2013479.","journal-title":"Am Fam Physician"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.18603"},{"key":"e_1_3_4_45_1","volume-title":"Health Technology Assessment (HTA).","author":"Canadian Agency for Drugs and Technologies in Health","year":"2023","unstructured":"Canadian Agency for Drugs and Technologies in Health. Lutetium (177Lu) Vipivotide Tetraxetan (Pluvicto). CADTH reimbursement review therapeutic area: metastatic castration-resistant prostate cancer. Health Technology Assessment (HTA). (PC0297CL). 2023."},{"key":"e_1_3_4_46_1","article-title":"Commercial reimbursement benchmarking: commercial payment rates for medical services as a percentage of Medicare fee-for-service rates","author":"Marshall S","year":"2024","unstructured":"Marshall S, Zhou D, Anderson C, et al. Commercial reimbursement benchmarking: commercial payment rates for medical services as a percentage of Medicare fee-for-service rates. Milliman Insight. 2024. [Internet]. Available from: https:\/\/www.milliman.com\/en\/insight\/commercial-reimbursement-benchmarking-medicare-ffs-rates","journal-title":"Milliman Insight"},{"key":"e_1_3_4_47_1","unstructured":"Chavarriaga J. ASCO GU. Time from medication order to administration of cabazitaxel vs. lutetium Lu-177 vipivotide tetraxetan in patients with metastatic castration-resistant prostate cancer (mCRPC). 2025. UroToday.com2025."},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.72.1076"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.09.105"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.125.271825"}],"container-title":["Journal of Medical Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13696998.2026.2709297","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/13696998.2026.2709297","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13696998.2026.2709297","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T10:03:40Z","timestamp":1786097020000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13696998.2026.2709297"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,7]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12,31]]}},"alternative-id":["10.1080\/13696998.2026.2709297"],"URL":"https:\/\/doi.org\/10.1080\/13696998.2026.2709297","relation":{},"ISSN":["1369-6998","1941-837X"],"issn-type":[{"value":"1369-6998","type":"print"},{"value":"1941-837X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,7]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-04-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}